TRex Bio is a biotechnology company that treats diseases like cancer, fibrotic by studying human tissues.
TRex Bio has raised $84.0M in total funding. The most recent round was Series B. The last funding was announced in November 2024.
TRex Bio's investors include Eli Lilly, SV Health Investors, Polaris Partners, Agent Capital, Alexandria Venture Investments.
TRex Bio is headquartered in South San Francisco, United States.
TRex Bio is a biotechnology company that treats diseases like cancer, fibrotic by studying human tissues.
TRex Bio is at the Series B stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"TRex Bio — Funding & Investors." VCBacked, November 13, 2024, https://www.vcbacked.co/company/trex-bio. Accessed August 14, 2026.
VCBacked. (2024). TRex Bio — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/trex-bio
{{cite web |title=TRex Bio — Funding & Investors |url=https://www.vcbacked.co/company/trex-bio |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated